NCT00918034 - Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Benign Prostatic HyperplasiaLower Urinary Tract Symptoms

Interventions

DRUG

talaporfin sodium

LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)

DEVICE

Transurethral illumination with light emitting diodes

A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes

PROCEDURE

Placement

Placement of device in prostate urethra

Trial Locations (8)

Royal Brisbane and Women's Hospital Center of Clinical Research, Herston

Bayside Urology, Mentone

Canterbury Urology Research Trust Hiatt Chambers St. George's Medical Centre, Christchurch

Roundhay Medical Centre, Nelson

Tauranga Urology Research, Ltd., Tauranga

Wellington Urology Research Group Wakefield Urology, Wellington

Kensington Hospital Cardinal Points Specialist Centre, Whangarei

Princess Alexandra Hospital, Wolloongabba